Weeks 1 to 4: Starting Dose Titration Starting dose is 0.25 milligrams of semaglutide weekly, plus 1,000 micrograms of B12
Contact your GP or healthcare team if you experience: Persistent diarrhoea lasting more than 4872 hours, or diarrhoea accompanied by signs of dehydration (dizziness, dark urine, dry mouth) Severe or worsening abdominal pain, particularly if it radiates to the back this may rarely indicate pancreatitis, a recognised risk associated with GLP-1 receptor agonists Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice), which may suggest gallbladder disease a known class-related concern with GLP-1-based therapies Blood in your stools or black, tarry stools, which require urgent investigation Persistent vomiting that prevents you from keeping fluids down Unexplained significant weight loss beyond what is expected from treatment Symptoms that are severely impacting your daily life or quality of life Seek emergency care (call 999 or go to A&E) if you develop: Sudden, severe abdominal pain Severe abdominal distension, inability to pass wind or stools, or signs of possible bowel obstruction Signs of serious dehydration or collapse Chest pain alongside GI symptoms If you are unsure whether your symptoms require emergency attention, contact NHS 111 for urgent advice
Pancreatitis GLP-1 drugs have been linked to an increased risk of pancreatitis, a potentially life-threatening condition characterized by inflammation of the pancreas
We understand the unique journey of weight loss patients
